Recently, two studies published in the Journal of The American Medical Association investigated the return on investment associated with coverage of GLP-1 agonists in the treatment of obesity. The study titled “Fiscal Impact of Expanded Medicare Coverage for GLP-1 Receptor Agonists to Treat Obesity” evaluated ...
On April 16, 2025, the Department of Commerce announced that it had initiated an investigation into the effects pharmaceutical ingredients and products have on national security. The Department’s investigation is likely to focus on several ...
On April 15, 2025, President Trump issued an Executive Order (EO) titled “Lowering Drug Prices by Once Again Putting America First”, introducing several concepts aimed at lowering the cost of prescription medications in the United States...
At ProAct, we continue to enable affordable access to biosimilars and help ensure a smooth transition for patients starting these innovative products. Our thoughtful and comprehensive approach to include inflammatory biosimilars on our ...
On March 20, 2025, Johnson & Johnson’s Tremfya® (guselkumab) received FDA approval for a label expansion for the treatment of Crohn’s Disease (CD). Tremfya® is the first and only interleukin (IL)-23 inhibitor offering both subcutaneous ...
